Axis-Shield's vitamin B12 test backed by trial; could boost sales in $50m market
This article was originally published in Clinica
Executive Summary
A study supports the use of Axis-Shield's test for Active-B12 as a diagnostic for vitamin B12 deficiency in elderly patients. Axis-Shield has recently launched this test, and will be hoping that the trial data will help the company penetrate this market.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.